



27 September 2018

Pharmaceuticals & Biotechnology



Source: Eikon Thomson Reuters

Market data

EPIC/TKR	AGY
Price (p)	24.0
12m High (p)	39.5
12m Low (p)	23.0
Shares (m)	636.2
Mkt Cap (£m)	152.7
EV (£m)	140.2
Free Float*	39%
Market	AIM

*As defined by AIM Rule 26

Description

Allergy Therapeutics (AGY) provides information to professionals related to prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination. The emphasis is on treating the underlying cause and not just the symptoms.

Company information

CEO	Manuel Llobet
CFO	Nick Wykeman
Chairman	Peter Jensen

+44 1903 845 820

www.allergytherapeutics.com

Key shareholders

Directors	0.8%
Abbott Labs	37.8%
Southern Fox	22.7%
Odey	6.9%
Invesco	4.5%

Diary

Nov'18	AGM
1H'19	Phase III PQ Birch trial

Analysts

Martin Hall	020 7194 7632	mh@hardmanandco.com
Dorothea Hill	020 7194 7626	dmh@hardmanandco.com
Grégoire Pavé	020 7194 7628	gp@hardmanandco.com

ALLERGY THERAPEUTICS

2018 full-year results: solid growth

AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a 'named-patient' basis. The Phase III trial, designed to obtain approval for PQ Birch as a biologic in Europe, is well advanced and will report data by the end of 2018. As discussed at the interim stage, underlying sales growth was affected by a low pollen season in central Europe. Full-year results suggest that this has remained a difficult market, but one in which AGY has continued to gain market share.

- **Strategy:** AGY is a fully integrated pharmaceutical company focused on the treatment of allergies. There are three parts to its strategy: continued development of its European business via investment or opportunistic acquisitions; the US PQ opportunity; and further development of its pipeline.
- **FY'18 results:** Underlying sales growth in the year to end-June 2018 was 3.5%, which was boosted to 6.6% on a reported basis to £68.3m (£64.1m). Given a weak and short pollen season in spring/summer 2017 and a correspondingly tough market, this was a good performance, with 1pp market share growth.
- **Profit:** Careful control of marketing and operational costs, combined with timing of R&D, resulted in stronger net cash of £12.5m (£18.8m) at 30 June 2018. As a result, pre-tax profit emerged at -£6.5m in 2018, compared with our forecast -£9.1m. Excluding R&D, operating profit improved 26% to £9.6m.
- **Risks:** AGY's primary risk lies in the timings of the regulatory approval process, mostly outside of its control, related to the PQ Birch immunotherapy and the European TAV process for full approval. Ongoing trials do represent a risk, but this is limited by the products' use on a named-patient basis.
- **Investment summary:** AGY is going through an exciting period. It has a clear vision, is gaining market share from competitors, and is leading the race to have its products fully approved and regulated as biologicals – first in Europe, then in the US, where the regulators are demanding change. Read-out from the EU Phase III PQ Birch trial in 2018 will provide the next major value inflection point.

Financial summary and valuation

Year-end June (£m)	2016	2017	2018	2019E	2020E	2021E
Sales	48.5	64.1	68.3	73.0	78.4	85.5
R&D investment	-16.2	-9.3	-16.0	-18.0	-20.0	-15.0
Underlying EBIT	-12.3	-2.9	-6.4	-7.8	-8.9	-2.0
Reported EBIT	-12.5	-2.6	-7.4	-8.8	-9.9	-3.0
Underlying PBT	-12.5	-3.0	-6.5	-8.1	-9.2	-2.4
Statutory PBT	-12.2	-2.7	-7.5	-9.1	-10.2	-3.3
Underlying EPS (p)	-2.4	-0.5	-1.1	-1.2	-1.6	-0.5
Statutory EPS (p)	-2.3	-0.4	-1.3	-1.4	-1.6	-0.5
Net (debt)/cash	20.0	18.8	12.5	13.8	1.7	-29.0
Capital increase	11.0	0.0	0.0	10.4	0.3	0.3
P/E (x)	-10.2	-51.2	-21.8	-19.6	-15.4	-48.8
EV/sales (x)	2.9	2.2	2.1	1.9	1.8	1.6

Source: Hardman & Co Life Sciences Research

Table of contents

Full-year 2018 results.....	3
European sales.....	4
Clinical update	6
Strategy	6
Newsflow.....	7
Financials and investment case	8
Placing, post-period-end.....	8
Changes to forecasts.....	8
Profit & Loss.....	9
Balance sheet.....	10
Cashflow	11
Disclaimer	13
Status of Hardman & Co's research under MiFID II	13

Full-year 2018 results

Financials – key features

- ▶ **Underlying sales growth:** 2018 group sales were slightly below our currency-adjusted forecast of £70.2m, reaching £68.3m (£64.1m) for the full-year. This represents 3.5% growth at constant exchange rates (CER) and reflects a good performance in a challenging period for the European allergy market.
- ▶ **Costs:** COGS, G&A and R&D spend were all lower than we had forecast. The timing of R&D spend has been affected by the Phase III PQ Birch trial, now expected to report data towards the end of the year. Investment in compliance, rent and incentives pushed up administration expenses 3% on 2017.
- ▶ **Underlying EBIT:** Careful control of costs, notably marketing, and the delays in spend on clinical trials, kept the EBIT above expectations, at -£6.38m. However, operating losses did increase on 2017, by £3.49m, due to increasing R&D spend; accordingly, pre-R&D EBIT improved 26% on 2017 to ca.£9.6m (£6.4m).
- ▶ **Cash balance:** On 30 June 2018, AGY held a cash balance of £15.5m (£22.1m), £3.7m better than our forecasts made prior to the July trading statement. This was helped by both the control of costs and by improvements in working capital.

Operations – key features

- ▶ **PQ Grass trial:** The Phase II PQ Grass trial was completed in the second half of fiscal 2018. The optimal dose was identified, which means that it can now progress to a pivotal trial.
- ▶ **PQ Birch trial:** The pivotal Phase III PQ Birch trial has also been completed, and the results are currently being analysed by the CRO. This has resulted in a minor delay in the reporting of top-line data, which are now expected by the end of 2018.
- ▶ **Acarovac dust mite:** Phase I trial was initiated in February, with data expected in fiscal 1H'19.

2018 results – actual vs expectations					
Year to June (£m)	2017 actual	2018 actual	Change %	2018 forecast	Delta Δ
Sales	64.14	68.35	6.6%	*70.2	-1.9
COGS	-16.77	-17.01	1.4%	-17.46	0.45
Marketing	-26.89	-27.13	0.9%	-26.94	-0.19
Product profitability	20.48	24.20	18.2%	23.94	0.26
Product margin	31.9%	35.4%	11.0%	35.0%	0.00
G&A	-14.08	-14.56	3.4%	-15.41	0.85
R&D	-9.30	-16.02	72.2%	-17.50	1.48
Underlying EBIT	-2.89	-6.38	120.6%	-8.97	2.60
Underlying EPS (p)	-0.47	-1.10	86.5%	-1.55	0.45
Net cash/(debt)	18.8	12.48	-33.6%	12.17	0.31

*Forecast prior to company trading statement made on 12 July 2018
Source: Hardman & Co Life Sciences Research

European sales

Growth in a tough market


At the end of calendar 2017, both AGY and its main competitors reported that the allergy market had been flat, for various reasons, including a shorter and weaker pollen season in the spring and summer of 2017. As such, AGY's sales growth of 3.5% at CER in fiscal 2018 demonstrates a strong performance. It represents a 1pp increase to a 14% market share (in the nine territories in which it makes direct sales, excluding the UK and Switzerland). Careful control of costs in the period, and a delay in R&D spend, generated a strong net cash position of £12.5m at the period-end, which, although lower than the prior period, was better than anticipated. This kept underlying EBIT above expectations, at -£6.38m.

Major markets

Germany is still by far the biggest market for AGY's products – 6% CER sales growth in the year meant that the country now represents 61% of the group's revenues. Expansion of existing and new markets means that AGY is reducing its exposure to Germany, although because its products are progressing through the TAV regulatory process, trial results are likely to have the largest impact in this market.

Sales in all main European markets grew in FY'18, with the exception of Italy, where sales declined 10.4%, from €6.48m/£5.54m in FY'17 to €5.81m/£5.14m in FY'18. The reason for this was not disclosed, although there has been reducing reimbursement in Italy, which is affecting demand. It has been one of the weakest markets for some years, although AGY appears to be maintaining its share of the market.

Geographical sales analysis




Figures are based on consolidated reported sales figures
Source: Allergy Therapeutics, Hardman & Co Life Sciences Research

Product performance

AGY's trading performance remains very strong. When R&D costs are excluded, FY'18 underlying operating profit improved by 26% to £9.6m (£6.4m). Its allergy immunotherapies are currently sold on a named-patient basis in Europe (it has no products licensed for sale in the US), where they are highly competitive, being convenient short-course treatments. Underlying operating profits were aided in FY'18 by improving product margins, 35.4% (31.9%), driven by containment of selling and marketing costs.

Half-year sales trend and CER growth rates



Source: Hardman & Co Life Sciences Research

Pollinex immunotherapies



Pollinex Quattro




Pollinex

Source: Allergy Therapeutics

Despite a difficult market in 2H'17 and 1H'18, associated with the weak 2017 pollen season, there was an increase in sales in 1H'18, which grew 1% on the comparable period, and some recovery in 2H'18, with 8% growth compared with 2H'17.

The Pollinex Quattro immunotherapy brand in Europe (PQ Grass and Trees) remains the company's biggest seller, with ca.£29m in sales in the 12 months to June 2018. Although an earlier version of PQ, not being based on Monophosphoryl Lipid A (MPL), Pollinex also continues to sell well, bring in approx. £12m.

Product sales analysis



Percentages reported by company

Source: Allergy Therapeutics, Hardman & Co Life Sciences Research


Clinical update

Strategy

Regulators in both the EU, via the Therapieallergene-Verordnung (TAV), and in the US (via the FDA's CBER) are instilling improved regulation in their respective markets. AGY is as well placed as any company to reap the benefits, being very advanced in terms of trials. Driven by the Paul Ehrlich Institute (PEI) and based on EU legislation, the TAV commenced in 2008, towards having fully approved allergy vaccines. All 10 vaccines submitted by AGY are still in the TAV process, with the Phase III PQ Birch trial being pivotal in achieving the first fully approved allergy vaccine in Europe.

PQ Grass trial

As part of an agreed programme with both the TAV and the FDA, AGY has undertaken a Phase II dose-ranging study with Modified Allergen Tyrosine Absorbed (MATA) MPL (PQ Grass). Headline data provided everything that AGY could have hoped for: a strong dose-response relationship ($p < 0.001$, extremely well tolerated, and an excellent adherence rate ($> 95\%$). Results allowed the company to identify the optimal dose for Phase III trials, subject to regulatory discussions. Although overall protocols for the Phase III trials in the EU and the US might be slightly different, they are likely to use the same dose when they start in 1H'19. The results will make upcoming discussions with the respective regulators somewhat easier, paving the way for commencement of the final Phase III trials which, in turn, open the door to PQ Grass becoming the first ultra-short-course allergy immunotherapy product to be registered in both Europe and the US.



Source: Allergy Therapeutics

PQ Birch trial

Recruitment for the pivotal Phase III PQ Birch study, which is designed to evaluate safety and efficacy, was fully achieved in 2018. 560 patients from 59 centres in four European countries were immunised and assessed during the birch pollen season (May to July 2018) to measure any rhinoconjunctivitis symptoms. Results are now due by the end of calendar 2018, representing the next major value inflection point.

AGY's immunotherapy pipeline and products

	Pre-clinical	Phase I	Phase II	Phase III	Market/Registered	Also available as a Named Patient Product
Grass MATA	EU	Short-course SCIT				
Tree MATA	EU	Short-course SCIT				
Ragweed MATA	CA	Short-course SCIT				
Bee Venom SCIT	EU	Short-course SCIT				
Wasp Venom SCIT	EU	Short-course SCIT				
Grass MATA MPL	EU, US	Short-course Grass SCIT with MPL				✓
Birch MATA MPL	EU	Short-course Birch SCIT with MPL				✓
Ragweed MATA MPL	US	Short-course Ragweed SCIT with MPL				✓
Trees MATA MPL	US	Short-course Tree SCIT with MPL				✓
Oral Grass, Trees & House Dust Mite		Sublingual immunotherapy with flexible-dosing				✓
Modified Mite Platform		Short-course modified Allergen HDM SCIT + MPL				✓
Peanut SCIT		Short-course Peanut SCIT				

Source: Allergy Therapeutics

Newsflow

Preparation for US market: Grass MATA MPL

Now that the Phase II trial has completed, preparations for the Phase III G306 clinical study are underway. It is expected to start enrolling in the autumn of 2019 (fiscal 1H'20) and to generate results during 2020. Depending on the timing of the data, a regulatory submission late 2020/early 2021 may allow for a launch during 2021. In line with the planned launch, AGY has its Type C regulatory meeting with the FDA's Center for Biologics Evaluation and Research (CBER) in 1H'19 (autumn 2018).

The US allergy market, estimated at \$2bn p.a., presents an excellent opportunity for the group. The main competition for grass immunotherapies in the US is from tablets manufactured by ALK and Stallergenes Greer. There are no registered subcutaneous allergy immunotherapy (SCIT) products for grass, and injected immunotherapies appear to be preferred by US physicians. A fully registered short-course product would provide an enhanced safety profile, alongside improved patient outcomes (convenience, adherence and wellbeing). Based on a potential price of \$2,000 per treatment and a conservative 1% target market, Grass MATA MPL could potentially achieve sales of ca.\$400m in the US alone.

Pipeline

During fiscal 2018, good progress was made in the development of the pipeline products. For instance, Acarovac for house dust mite allergies is in Phase I, and should read out in 1H'19, and Polyvac for peanut allergies is expected to begin its first-in-human trials in calendar 2019. Furthermore, PQ Ragweed and PQ Trees are being assessed for development towards the US market.

Expected newsflow		
Calendar year	Product	Event
2H'18	PQ Grass	End of Phase II meeting with FDA CBER
4Q'18	PQ Birch	Phase III headline results for European launch
1H'19	House dust mite MPL	Phase I trial headline data
1H'19	Polyvac Peanut	Completion of industrial manufacture scale up
2019	House dust mite MPL	Initiation of Phase II trial
2019	Grass MATA MPL	Start G306 Phase III trial

Source: Hardman & Co Life Sciences Research

Financials and investment case

Placing, post-period-end

As part of its strategy to invest in the Phase III Grass trial, AGY undertook an equity raise on 19 July 2018. Via a Placing and Subscription, it raised £10.6m gross through the issue of 40,000,000 new Ordinary 1p shares at 26.5p per share, with existing and new shareholders. This represented a premium of 0.4% to the average mid-market price over the 60 days up to and including 18 July 2018. The new shares represented 6.3% of the enlarged share capital and were admitted to AIM on 25 July 2018.

Changes to forecasts

- ▶ **Sales:** Since sales came in below our expectations by ca.£1.9m for FY'18, there was a knock-on effect on future expectations, and we have taken the conservative approach to expectations for the forecast period. These will be strongly influenced by the timing of approval of PQ Birch in Europe and of Grass MATA MPL in the US.
- ▶ **R&D spend:** Our expectations for R&D spend in 2019 remain constant, because although some of the PQ Birch Phase III trial costs will now be in 2019, this has been compensated by cost savings related to the trial. However, we have increased our forecasts for 2020, in particular, to reflect the ongoing late-phase grass trials, of which US-based costs are likely to be high, and progress towards the house dust mite trials.
- ▶ **Profit:** AGY is approaching profitability in 2020, according to our model, although this will, of course, be greatly influenced by the progress of clinical trials and the quantum of R&D investment.

Changes to forecasts				
Year-end June (£m)	2018	2019E	2020E	2021E
Group sales				
Old	68.35	76.51	85.74	152.47
New		73.04	78.39	85.54
Change		-3.48	-7.35	-66.93
R&D				
Old	-16.02	-18.00	-8.00	-12.00
New		-18.00	-20.00	-15.00
Change		0.00	-12.00	-3.00
U/L pre-tax profit				
Old	-6.54	-8.90	5.57	32.06
New		-8.08	-9.21	-2.36
Change		0.82	-14.78	-34.43
U/L EPS (p)				
Old	-1.10	-1.35	0.75	4.76
New		-1.22	-1.55	-0.49
Change		0.13	-2.31	-5.25

Source: Hardman & Co Life Sciences Research

Profit & Loss

- ▶ **Sales:** We estimate underlying growth of 3.5% in 2018 to be followed by mid to high single-digit growth in the next two years, driving further market share gains.
- ▶ **R&D:** We expect investment in fiscal 2019 and 2020 to grow R&D spend between 11% and 12% on previous years, and this is likely to be more biased towards the second half of the year due to the timing of clinical trials.
- ▶ **Forex:** All our forecasts are based on constant currency to provide a picture of underlying performance, as indicated in the following table.

Profit & Loss account						
Year-end June (£m)	2016	2017	2018	2019E	2020E	2021E
GBP:EUR	1.338	1.171	1.130	1.130	1.130	1.130
GBP:USD	1.484	1.281	1.341	1.341	1.341	1.341
Sales	48.51	64.14	68.35	73.00	78.40	85.50
COGS	-14.07	-16.77	-17.01	-17.89	-18.42	-19.75
Gross profit	34.44	47.37	51.33	55.11	59.98	65.75
Marketing	-20.22	-26.89	-27.13	-29.73	-32.69	-35.24
Product profit	14.22	20.48	24.20	25.42	27.29	30.54
Product margin	29.3%	31.9%	35.4%	34.8%	34.8%	35.7%
G&A	-10.33	-14.08	-14.56	-15.27	-16.23	-17.54
R&D	-16.22	-9.30	-16.02	-18.00	-20.00	-15.00
EBITDA	-10.68	-1.42	-4.82	-5.82	-6.92	0.03
Depreciation	-1.43	-1.48	-1.56	-2.02	-2.02	-2.02
Other income	0.00	0.00	0.00	0.00	0.00	0.00
Underlying EBIT	-12.34	-2.89	-6.38	-7.84	-8.94	-1.99
Share-based costs	-0.33	-0.70	-0.99	-0.99	-0.99	-0.99
Exceptional items	0.14	1.00	0.00	0.00	0.00	0.00
Statutory EBIT	-12.53	-2.60	-7.36	-8.83	-9.93	-2.98
Net financials	-0.11	-0.07	-0.17	-0.24	-0.27	-0.37
Pre-tax profit	-12.45	-2.97	-6.54	-8.08	-9.21	-2.36
Exceptional items	0.43	0.00	0.00	0.00	0.00	0.00
Reported pre-tax	-12.21	-2.67	-7.53	-9.07	-10.19	-3.35
Tax payable/credit	-0.86	0.19	-0.01	0.34	0.22	-0.09
Minorities	0.00	0.00	0.00	0.00	0.00	0.00
Underlying net income	-13.46	-2.78	-6.55	-7.74	-9.89	-3.13
Statutory net income	-13.07	-2.48	-7.53	-8.73	-9.97	-3.44
Ordinary shares:						
Period-end (m)	589.2	594.1	596.2	636.2	636.2	636.2
Weighted average (m)	570.3	592.2	595.1	633.4	636.2	636.2
Fully diluted (m)	589.2	615.1	625.2	668.5	679.2	691.2
Underlying basic EPS (p)	-2.36	-0.47	-1.10	-1.22	-1.55	-0.49
Statutory basic EPS (p)	-2.29	-0.42	-1.27	-1.38	-1.57	-0.54
U/I fully-diluted EPS (p)	-2.28	-0.45	-1.05	-1.16	-1.46	-0.45
Stat. fully-diluted EPS (p)	-2.22	-0.40	-1.20	-1.31	-1.47	-0.50
DPS (p)	0.00	0.00	0.00	0.00	0.00	1.00

Source: Hardman & Co Life Sciences Research

Balance sheet

- ▶ **Net cash/(debt):** At 30 June 2018, AGY had net cash of £12.5m, composed of a cash balance of £15.5m less debt, mostly long-term, of -£2.4m. The debt is largely within AGY's Alerpharma subsidiary in Spain, providing a natural currency hedge.
- ▶ **Seasonality:** There is a natural first-half bias to performance due to the seasonality of allergy treatment, with more cash being generated in the first half of the year from operations (ex-R&D).
- ▶ **R&D:** AGY's accounting policy is to write off R&D investment in the year in which the expense is incurred. Solely for the calculation of invested capital and NOPLAT, we add back R&D and amortise it over eight years to enable a direct comparison of ROIC between all the companies under coverage.

Balance sheet						
@30 June (£m)	2016	2017	2018	2019E	2020E	2021E
Shareholders' funds	30.32	29.97	23.03	14.31	4.33	0.89
Cumulated goodwill	0.00	0.00	0.00	0.00	0.00	0.00
Total equity	30.32	29.97	23.03	14.31	4.33	0.89
Share capital	0.60	0.60	0.61	0.61	0.61	0.61
Reserves	29.73	29.36	22.43	13.70	3.72	0.29
Capitalised R&D	21.13	25.42	34.69	43.91	52.89	55.32
Minorities	0.00	0.00	0.00	0.00	0.00	0.00
Provisions/liabilities	1.44	0.70	0.38	0.38	0.38	0.38
Deferred tax	0.33	0.35	0.31	0.31	0.31	0.31
Long-term loans	3.07	2.94	2.41	2.41	2.41	2.41
Short-term debt	0.30	0.39	0.64	0.64	0.64	0.64
less: Cash	23.41	22.12	15.53	16.84	4.71	-25.96
less: Deposits	0.00	0.00	0.00	0.00	0.00	0.00
less: Non-core invests.	4.05	4.59	5.04	5.04	5.04	5.04
Invested capital	39.32	42.66	51.24	50.43	61.56	91.21
Fixed assets	9.67	9.67	10.10	10.84	12.74	19.83
Intangible assets	2.08	2.07	1.54	1.08	0.62	0.16
Capitalised R&D	21.13	25.42	34.69	43.91	52.89	55.32
Goodwill	3.27	3.39	3.41	3.41	3.41	3.41
Inventories	7.69	7.48	8.81	9.41	10.10	11.02
Trade debtors	4.68	4.34	3.42	3.66	3.92	4.28
Other debtors	1.84	3.52	3.17	4.17	5.17	6.17
Tax liability/credit	-1.43	-1.43	-1.43	-1.43	-1.43	-1.43
Trade creditors	-3.11	-2.88	-4.32	-4.55	-4.68	-5.02
Other creditors	-6.51	-8.92	-8.14	-20.08	-21.19	-2.52
Debtors less creditors	-4.53	-5.37	-7.30	-18.23	-18.20	1.48
Invested capital	39.32	42.66	51.24	50.43	61.56	91.21
Net cash/(debt)	20.04	18.80	12.48	13.78	1.65	-29.01

Source: Hardman & Co Life Sciences Research

Cashflow

- ▶ **Cash outflow:** The increased R&D expenditure in the next three years offsets cash generated from product sales, resulting in negative cash-flow in the forecast period.
- ▶ **R&D investment:** Two important Phase III trials are currently under way, or soon to begin, for which stage payments will be made in fiscal 2019 and 2020. Forecasts are based solely on the planned clinical trial programmes; however, in all likelihood, further clinical trials for the pipeline (including for house dust mites) will be performed in fiscal 2020, which may require further capital.
- ▶ **Capital increase:** The recent capital increase provides sufficient funds to undertake the Phase III PQ Grass trials. However, given an expansion in the number of clinical trials being scheduled, it is inevitable that AGY will require more funds in the future. This could come from one of, or a combination of, equity, debt and licensing/distribution deals.

Cashflow						
Year-end June (£m)	2016	2017	2018	2019E	2020E	2021E
Trading profit	-12.34	-2.89	-6.38	-7.84	-8.94	-1.99
Depreciation	1.43	1.48	1.56	1.56	1.56	1.56
Amortisation	0.24	0.46	0.46	0.46	0.46	0.46
<i>Inventories</i>	-0.59	0.33	-1.33	-0.60	-0.69	-0.92
<i>Receivables</i>	-0.37	1.00	3.30	-3.66	-0.27	0.00
<i>Payables</i>	-0.50	0.82	-1.76	4.55	0.13	0.00
Change in working capital	-1.45	2.16	0.21	0.29	-0.82	-20.82
Exceptionals/provisions	0.00	0.00	0.00	0.00	0.00	0.00
Disposals	0.00	0.00	0.01	0.00	0.00	0.00
Other	-0.15	0.11	0.26	0.00	0.00	0.00
Company op cashflow	-12.28	1.32	-3.88	-5.54	-7.74	-21.72
Net interest	-0.39	-0.18	-0.27	-0.24	-0.27	-0.37
Tax payable/credit	0.09	-1.10	0.37	-0.64	-0.51	0.22
Operational cashflow	-12.57	0.03	-3.78	-6.41	-8.52	-21.87
Capital expenditure	-1.23	-1.50	-2.01	-2.31	-3.46	-8.65
Capitalised R&D	0.00	0.00	0.00	0.00	0.00	0.00
Sale of fixed assets	0.00	0.00	0.00	0.00	0.00	0.00
Free cashflow	-13.80	-1.47	-5.79	-8.72	-11.98	-30.52
Dividends	0.00	0.00	0.00	0.00	0.00	0.00
Acquisitions	0.00	-0.23	-0.18	-0.10	-0.10	-0.10
Disposals	0.00	0.00	0.00	0.00	0.00	0.00
Other investments	-0.26	-0.26	-0.37	-0.30	-0.30	-0.30
CF after investments	-14.06	-1.95	-6.33	-9.12	-12.38	-30.92
Share repurchases	0.00	0.00	0.00	0.00	0.00	0.00
Share issues	10.97	0.03	0.00	10.43	0.25	0.25
Currency effect	3.00	0.67	0.01	0.00	0.00	0.00
Borrowings acquired	0.00	0.00	0.00	0.00	0.00	0.00
Change in net debt	-0.10	-1.25	-6.32	1.31	-12.13	-30.67
Opening net cash	20.14	20.04	18.79	12.47	13.78	1.65
Closing net cash	20.04	18.79	12.47	13.78	1.65	-29.02
Hardman FCF/share (p)	-2.20	0.01	-0.64	-1.01	-1.34	-3.44

Source: Hardman & Co Life Sciences Research

Notes

Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legals/research-disclosures>. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)

Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'

The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-2031.pdf>

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.



research@hardmanandco.com

35 New Broad Street
London
EC2M 1NH

+44(0)20 7194 7622

www.hardmanandco.com